Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma
Samuel S. Freeman(Broad Institute), Moshe Sade-Feldman(Broad Institute), Jaegil Kim(Broad Institute), Chip Stewart(Broad Institute), Anna Gonye(Broad Institute), Arvind Ravi(Broad Institute), Monica Arniella(Broad Institute), Irena Gushterova(Broad Institute), Thomas J. LaSalle(Broad Institute), Emily M. Blaum(Broad Institute), Keren Yizhak(Technion – Israel Institute of Technology), Dennie T. Frederick(Massachusetts General Hospital), Tatyana Sharova(Massachusetts General Hospital), Ignaty Leshchiner(Broad Institute), Liudmila Elagina(Broad Institute), Oliver Spiro(Broad Institute), Dimitri Livitz(Broad Institute), Daniel Rosebrock(Broad Institute), François Aguet(Broad Institute), Jian Carrot‐Zhang(Broad Institute), Gavin Ha(Fred Hutch Cancer Center), Ziao Lin(Broad Institute), Jonathan Chen(Broad Institute), Michal Barzily-Rokni(Massachusetts General Hospital), Marc R. Hammond(Massachusetts General Hospital), Hans C. Vitzthum von Eckstaedt(Massachusetts General Hospital), Shauna Blackmon(Massachusetts General Hospital), Yunxin J. Jiao(Broad Institute), Stacey Gabriel(Broad Institute), Donald P. Lawrence(Massachusetts General Hospital), Lyn M. Duncan(Massachusetts General Hospital), Anat Stemmer‐Rachamimov(Massachusetts General Hospital), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Keith T. Flaherty(Massachusetts General Hospital), Ryan J. Sullivan(Massachusetts General Hospital), Genevieve M. Boland(Massachusetts General Hospital), Matthew Meyerson(Broad Institute), Gad Getz(Broad Institute), Nir Hacohen(Broad Institute)
Cited by 34Open Access
Abstract
. Overall, RNA or DNA-based models combining immune and tumor measures improve predictions of melanoma CPB outcomes.
Related Papers
No related papers found
Powered by citation graph analysis